Macrophage migration inhibitory factor is associated with positive cultures in patients with sepsis after cardiac surgery

Shock

Volumn 24, Issue 4, 2005, Pages 313-317

  Furtado De Mendonça Filho, Hugo Tannus ^a,c   Gomes, Gleice Silva ^a   Mattos Nogueira, Pedro Miguel ^a   De Oliveira Fernandes, Marco Aurelio ^a   Tura, Bernardo Rangel ^b   Santos, Marisa ^a   Castro Faria Neto, Hugo Caire ^c  

^a HOSPITAL PRÓ CARDÍACO   (Brazil)

^b INSTITUTO NACIONAL DE CARDIOLOGIA   (Brazil)

^c INSTITUTO OSWALDO CRUZ   (Brazil)

Author keywords

Cardiac surgery; Cytokine; Microbiological screening; MIF; Sepsis

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 10; INTERLEUKIN 6; MACROPHAGE MIGRATION INHIBITION FACTOR; MONOCYTE CHEMOTACTIC PROTEIN 1; PROCALCITONIN; TUMOR NECROSIS FACTOR ALPHA;

ACUTE PHASE RESPONSE; ARTICLE; BACTERIAL INFECTION; BACTERIUM CULTURE; CLINICAL ARTICLE; CYTOKINE PRODUCTION; DIAGNOSTIC VALUE; DISEASE MARKER; FEMALE; HEART SURGERY; HUMAN; MALE; MICROBIOLOGICAL EXAMINATION; MORTALITY; PROSPECTIVE STUDY; SEPSIS;

ACUTE-PHASE REACTION; AGED; ANTI-INFECTIVE AGENTS; BACTERIAL INFECTIONS; C-REACTIVE PROTEIN; CALCITONIN; CARDIAC SURGICAL PROCEDURES; CHEMOKINE CCL2; CYTOKINES; FEMALE; HUMANS; INFLAMMATION; INTERLEUKIN-10; INTERLEUKIN-6; MACROPHAGE MIGRATION-INHIBITORY FACTORS; MALE; MIDDLE AGED; PILOT PROJECTS; POSTOPERATIVE COMPLICATIONS; PROTEIN PRECURSORS; ROC CURVE; SEPSIS; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 26244461196     PISSN: 10732322     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.shk.0000180622.52058.3a     Document Type: Article

References (38)

1. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: Definitions for sepsis and multiple organ failure, and guidelines for innovative therapies in sepsis. Crit Care Med 20:864-874, 1992.
2. Moine P, Abraham E: Immunomodulation and sepsis: impact of the pathogen. Shock 22:297-308, 2004.
3. Marshall JC, Vincent JL, Fink MP, Cook DJ, Rubenfeld G, Foster D, Fisher CJ Jr, Faist E, Reinhart K: Measures, markers, and mediators: toward a staging system for clinical sepsis. A report of the Fifth Toronto Sepsis Roundtable, Toronto, Ontario, Canada, October 25-26, 2000. Crit Care Med 31:1560-1567, 2003.
4. Goris RJ, Te Boekhorst TP, Nuytinck JK, Gimbrere JS: Multiple organ failure: generalized autodestructive inflammation? Arch Surg 120:1109-1115, 1985.
5. Bone RC: Sepsis syndrome. New insights into its pathogenesis and treatment. Infect Dis North Am 5:793-805, 1991.
6. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR: Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 29:1472-1474, 2001.
7. Nashef SA, Roques F, Michel P, Gauducheau E, Lemeshow S, Salamon R: European system for cardiac operative risk evaluation (EuroSCORE). Eur J Cardiothorac Surg 16:9-13, 1999.
8. Tracey KJ, Lowry SF, Cerami A: Cachectin/TNF-α in septic shock and septic adult respiratory distress syndrome. Am Rev Respir Dis 138:1377-1379, 1988.
9. Meisner M, Rauschmayer C, Schmidt J, Feyrer R, Cesnjevar R, Bredle D, Tschaikowsky K: Early increase of procalcitonin after cardiovascular surgery in patients with postoperative complications. Intensive Care Med 28:1094-1102, 2002.
10. Dellinger RP, Calet JM, Masur H, Gerlach H, Calandra T, Cohen J, Gea-Banacloche J, Keh D, Marshall J, Parker MM, Ramsay G, Zimmermann JL, Vincent JL, Levy MM: Surviving sepsis campaign: guidelines for management of severe sepsis and septic shock. Intensive Care Med 30:536-555, 2004.
11. Rocke DA, Gaffin SL, Wells MT, Koen Y, Broack-Utine JG: Endotoxemia associated with cardiopulmonary bypass. J Thorac Cardiovasc Surg 93:832-837, 1987.
12. Calandra T, Echtenacher B. Le Roy D, Pugin J, Metz CN, Hultner L, Heumann D, Mannel D, Bucala R, Glauser MP: Protection from septic shock by neutralization of macrophage migration inhibitory factor. Nat Med 6:164-170, 2000.
13. Calandra T, Roger T: Macrophage migration inhibitory factor: a regulator of innate immunity. Nat Rev Immunol 3:791-799, 2003.
14. Bozza M, Satoskar AR, Lin G, Lu B, Humbles AA, Gerard C, David JR: Targeted disruption of migration inhibitory factor gene revels its critical role in sepsis. J Exp Med 189:341-346, 1999.
15. Bucala R: MIF rediscovered: cytokine, pituitary hormone and glucocorticoid-induced regulator of immune response. FASEB J 10:1607-1613, 1996.
16. Kini PM, Fernandez J, Causay RS, Lemole GM: Double-blind comparison of cefazolin and cephalotin in open-heart surgery. J Thorac Cardiovasc Surg 76:506-509, 1978.
17. Maki DG, Weise CE, Sarafin HW: A semiquantitative culture method for identification of catheter-related infection. N Engl J Med 296:1305-1309, 1977.
18. Jorgensen JH: Methodology for the serum bactericidal test; approved guideline, Ed 1. Global Consensus Standardization For Health Technologies, Wayne, PA 1999.
19. National Nosocomial Infectious Surveillance System Manual: CDC definitions for nosocomial infections. US Department of Health & Human Services, available at http://www.cdc.gov/ncidod/hip/NNIS/NosInfDefinitions.pdf, 1994.
20. Rangel-Frausto MS, Pittet D, Hwang T, Woolson RF, Wenzel RP: The dynamics of disease progression in sepsis: Markov modeling describing the natural history and the likely impact of effective antisepsis agents. Clin Infect Dis 27:185-190, 1998.
21. Massoudy P, Zahler S, Becker BF, Braun SL, Barankay A, Meisner H: Evidence of inflammatory responses of the lungs during coronary artery bypass grafting with cardiopulmonary bypass. Chest 119:31-36, 2001.
22. Whang KT, Vath SD, Nylen ES, Muller B, Qichang L, Tamarkin L, White JC: Procalcitonin and proinflammatory cytokine interactions in sepsis. Shock 12:265-273, 1999.
23. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM: CDC definitions for nosocomial infections. Am J Infect Control 16:128-140, 1988.
24. Matzinger P: An innate sense of danger. Semin Immunol 10:399-415, 1998.
25. Karlstad MD, Patteson SK, Guszcza JA, Langdon R, Chesney JT: Methylprednisolone does not influence endotoxin translocation during cardiopulmonary bypass. J Cardiothorac Vasc Anesth 7:23-27, 1993.
26. Kollef MH, Sharpless L, Vlasnik J, Pasque C, Murphy D, Frase VJ: The impact of nosocomial infections on patients' outcome following cardiac surgery. Chest 112:666-675, 1997.
27. Villa P, Sartor G, Angelini M, Sironi M, Conni M, Gnocchi P, Isetta AM, Grau G, Buurman W, vanTits LJH, Ghezzi P: Pattern of cytokines and pharmacomodulation in sepsis induced by cecal ligation and puncture compared with that induced by endotoxin. Clin Diagn Lab Immunol 2:549-553, 1995.
28. Klein D, Einspanier R, Bolder U, Jeschke MG: Differences in hepatic signal transcription pathway and cytokine expression between thermal injury and sepsis. Shock 20:536-543, 2003.
29. Roger T, David J, Glauser MP, Calandra T: MIF regulates innate immune responses through modulation of Toll-like receptor 4. Nature 414:920-924, 2001.
30. Bacher M, Meinhardt A, Lan HY, Mu W, Metz CN, Chesney JA, Calandra T, Gemsa D, Donnelly T, Atkins RC, Bucala R: Migration inhibitory factor expression in experimentally induced endotoxemia. Am J Pathol 150:235-246, 1997.
31. de Mendonca-Filho HTF, Gomes RV, Campos LAA, Tura B, Nunes EM, Gomes R, Bozza F, Bozza PT, Castro-Faria-Neto HC: Circulating levels of macrophage migration inhibitory factor are associated to mild pulmonary dysfunction following cardiopulmonary bypass. Shock 22:533-537, 2004.
32. Gando S, Nishihira J, Kemmotsu O, Kobayashi S, Morimoto Y, Matsui Y, Yasuda K: An increase in macrophage migration inhibitory factor release in patients with cardiopulmonary bypass surgery. Surg Today 30:689-694, 2000.
33. Lehmann LE, Novender U, Schroeder S, Pietsch T, von Spiegel T, Putensen C, Hoeft A, Stuber F: Plasma levels of macrophage migration inhibitory factor are elevated in patients with severe sepsis. Intensive Care Med 27:1412-1415, 2001.
34. Joshi PC, Poole GV, Sachdev V, Zhou X, Jones Q: Trauma patients with positive cultures have higher levels of circulating macrophage migration inhibitory factor (MIF). Res Commun Pathol Pharmacol 107:13-20, 2000.
35. Bozza FA, Gomes RN, Japiassú AM, Soares M, Castro-Faria-Neto HC, Bozza PT, Bozza MT: Macrophage migration inhibitory factor levels correlate with fatal outcome in sepsis. Shock 22:309-313, 2004.
36. Gando S, Nishihira J, Kobayashi S, Morimoto Y, Nanzaki S, Kemmotsu O: Macrophage migration inhibitory factor is a critical mediator of systemic inflammatory response syndrome. Intensive Care Med 27:1187-1193, 2001.
37. Assicot M, Gendrel D, Carsin H, Raymond J, Guilbaud J, Bohuon C: High serum procalcitonin concentrations in patients with sepsis and infection. Lancet 341:515-518, 1993.
38. Fasshauer M, Klein J, Kralisch S, Klier M, Lossner U, Bluher M, Paschke R: Monocyte chemoattractant protein I expression is stimulated by growth hormone and interleukin-6 in 3T3-L1 adipocytes. Biochem Biophys Res Commun 317:598-604, 2004.